On Apr. 6, 2020, Intravacc announced development of an intranasal vaccine against COVID-19 that will be developed through a newly established public private partnership that combines the vaccine development technology from Intravacc, and animal technologies from Wageningen Bioveterinary Research based in Lelystad, the Netherlands, and the coronavirus expertise from Dutch Utrecht University.